Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma

Frédérique Albarel1,2, Caroline Gaudy3, Frédéric Castinetti1,2, Tiphaine Carre3, Isabelle Morange1,2, Bernard Conte-Devolx1,2, Jean-Jacques Grob4 and Thierry Brue1,2

1Assistance Publique – Hôpitaux de Marseille (AP-HM), Hôpital Timone, Service d’Endocrinologie et Centre de Référence des Maladies Rares d’Origine Hypophysaire DEFHY, 13385 Marseille Cedex 15, Marseille, France, 2Aix-Marseille Université, CNRS, CRN2M-UMR7286, 13344 Marseille Cedex 15, Marseille, France and 3Aix-Marseille Université, Assistance Publique – Hôpitaux de Marseille (AP-HM), Hôpital Timone, Service de dermatologie, 13385 Marseille Cedex 15, Marseille, France

Correspondence should be addressed to T Brue
Email thierry.brue@univ-amu.fr

Abstract

Objective: Few data are published on the long-term follow-up of ipilimumab-induced hypophysitis, a cytotoxic T-lymphocyte antigen 4 antibody. We characterized hypophysitis in terms of clinical signs, endocrinological profile, and imaging at diagnosis and during a long-term follow-up.

Design and patients: Fifteen patients, treated for malignant melanoma and who presented ipilimumab-induced hypophysitis, were observed between June 2006 and August 2012 in Timone Hospital, Marseille.

Methods: Symptoms, pituitary function, and pituitary imaging at diagnosis of hypophysitis and during the follow-up were recorded.

Results: Of 131 patients treated with ipilimumab or a placebo, 15 patients (10 mg/kg in 11/15) presented with hypophysitis (≥ 11.5%) at 9.5 ± 5.9 weeks (mean ± s.d.) after treatment start, occurring in 66% after the third infusion. The main initial symptoms were headache (n = 13) and asthenia (n = 11). All patients but one had at least one hormonal defect: thyrotroph (n = 13), gonadotroph (n = 12), or corticotroph (n = 11) deficiencies. None had diabetes insipidus. Pituitary imaging showed a moderately enlarged gland in 12 patients. Clinical symptoms improved rapidly on high-dose glucocorticoids (n = 11) or physiological replacement doses (n = 4). At the end of follow-up (median 33.6 months, range 7–53.5), corticotroph deficiency remained in 13 patients, 11 recovered thyrotroph and ten gonadotroph functions. Pituitary imaging remained abnormal in 11 patients.

Conclusion: Ipilimumab-induced hypophysitis is a common side-effect with frequent hormonal deficiencies at diagnosis. Usually, hormonal deficiencies improved, except for corticotroph function. Patients receiving these immunomodulatory therapies should be closely monitored especially by systematic baseline hormone measurements after the third infusion and remain at a risk of adrenal insufficiency in the long-term.
variable pituitary defects), the infundibulum (infundibulo-neurohypophysitis with diabetes insipidus), or the entire pituitary gland (pan-hypophysitis) (2, 3). Diagnosis is most often presumptive: because surgery is unnecessary, this makes pathological analysis impossible. Moreover, currently available anti-pituitary antibodies do not have enough diagnostic accuracy as no specific antigen has been identified in this pathology (3, 4, 5). Diagnosis is thus based on the association between pituitary mass and tumor-related symptoms (headache and visual field defect), variable degrees of hypopituitarism, or hyper-prolactinemia (6).

A new etiology of hypophysitis has recently been described in association with a specific immunomodulatory therapy that uses human MABs against the cytotoxic T-lymphocyte antigen 4 (CTLA4 Ab). T-lymphocyte CTLA4 receptors enhance self-tolerance by downregulating the T-cell activation pathway, which could potentiate tumor development. By blocking the CTLA4 receptor, CTLA4 Ab promotes an immune response and antitumor activity (7, 8, 9). The use of ipilimumab, a CTLA4 Ab, was approved in 2011 by the US Food and Drug Administration for the treatment of advanced malignant melanoma: two recent phase-III studies have reported improved overall survival in metastatic melanomas (10, 11). Anti-CTLA4 Ab treatment, with doses ranging from 0.3 to 10 mg/kg, is currently being assessed in many clinical trials as a therapeutic agent for malignant melanoma, renal-cell carcinoma, prostate cancer, lung cancer, pancreatic adenocarcinoma, liver cancer, ovarian cancer, lymphoma, leukemia, and other hematological disorders and solid tumors (12). However, anti-CTLA4 Ab therapy is also responsible for increased autoimmunity (7, 8). The use of this drug is thus associated with multiple and variable immune-related adverse events (IRAEs), mainly concerning the gastro-intestinal tract, liver, skin, and endocrine system (hypophysitis, autoimmune thyroid disease, and primary adrenal insufficiency) (13, 14, 15).

In a recent pooled analysis of 325 patients treated with four infusions of 10 mg/kg ipilimumab, IRAEs were observed in 72.3%, with 25.2% of severe IRAEs (grade 3 or 4). Specific timing of occurrence was observed depending on tissue type: after 2–3 weeks for skin, later for gastrointestinal and hepatic IRAEs, and >9 weeks for hypophysitis (13). An association between the occurrence of IRAEs and relapse-free survival and a favorable response to therapy and tumor regression is still debated (16, 17, 18). A recent study has suggested a positive correlation between hypophysitis and survival using ipilimumab for metastatic melanoma (19).

Only a few cases of ipilimumab-induced hypophysitis have been described, mostly as case reports, although a few series have been published (12, 15, 19, 20, 21, 22). The largest studies have included, respectively, 13 and 17 patients (14 with hormonal data), but clinical, biological, and imaging data were often incomplete or partial, and/or the follow-up periods were short after initiation of ipilimumab (18, 19). As reported in a recent review (20), initial symptoms were usually related to tumor mass or hormone deficiencies, and rarely to visual disturbance or diabetes insipidus. Corticotroph and thyrotroph deficiencies were present in all cases, and gonadotroph deficiency was common in males. In these studies, the somatotroph axis and prolactin levels were rarely studied (12, 20, 23). Magnetic-resonance images (MRIs) were variable, from normal to typical hypophysitis; in most cases, pituitary enlargement was modest and decreased with glucocorticoid treatment (22, 24). These data have been confirmed in a recent series that found no diabetes insipidus in 17 patients with ipilimumab-induced hypophysitis. In this study, a majority of patients presented with headache and with thyrotroph and gonadotroph deficiencies at diagnosis (only seven of the 14 patients with hormonal data had corticotroph deficiency), with mild to moderate diffuse pituitary enlargement evident in the MRIs (19). Of note, very few follow-up data are available, making it difficult to determine the endocrine outcomes of such patients.

Our study was aimed at analyzing the clinical, biological, and imaging characteristics, and the long-term follow-up outcomes of 15 patients who presented with autoimmune hypophysitis induced by ipilimumab (CTLA4 Ab), given at 3 or 10 mg/kg, delivered for a malignant melanoma. These patients were followed at our center for a median of 33.6 months, range 7–53.5, enabling us to obtain long-term follow-up data.

**Patients and methods**

**Design and patients**

A total of 131 patients with a malignant melanoma were enrolled in this study from either ongoing trials or during temporary authorization for use (TAU). The study was conducted between June 2006 and August 2012 in the Department of Dermatology, La Timone Hospital (Marseille, France). Because several of these patients were included in trials that are still blinded, the real number of patients that received ipilimumab ranged from 87 to 131: this included 62 patients with stage-IV metastatic...
melanoma who were treated with ipilimumab at a dose of 3 mg/kg (TAU); 25 patients with stage-IV metastatic melanoma who were treated with variable doses ranging from 0.3 to 10 mg/kg; and an as-yet unknown (until unblinding) proportion of 44 patients with stage-III malignant melanoma (positive lymph nodes and no other evidence of metastatic disease spread) who received ipilimumab as an adjuvant therapy (10 mg/kg).

Written informed consent was obtained from all patients. Modalities of administration of ipilimumab depended on the stage of disease. Stage-IV patients received four infusions, with 3 weeks between each infusion, and a possibility of re-induction. In stage-III, the induction phase was similar (one treatment every 3 weeks, repeated four times), followed by a maintenance phase with an infusion every 3 months for up to 3 years.

Before starting treatment, all patients were initially evaluated for hormonal status. This included measurement of the following baseline hormone levels: free thyroxin (T4), thyroid-stimulating hormone (TSH), cortisol, and adrenocorticotropic hormone (ACTH) and testosterone (for men). Data were first retrospectively analyzed until September 2010. After this date, when a diagnosis of hypophysitis was suspected, patients were systematically referred, in a prospective manner, to the same endocrinologist who collected the follow-up clinical, biological, and imaging data, and advised on hormone treatments.

A diagnosis of hypophysitis was presumptive, based on the association between clinical symptoms (related to tumor mass or hormone deficiencies) and hormonal abnormalities or radiological signs at pituitary MRI or computed tomography (CT) scan evaluation (6). As no patient was treated surgically, none had pathological confirmation of the diagnosis of hypophysitis.

**Clinical, hormonal, and imaging evaluation**

Patients received close and systematic monitoring: this included clinical and biological (TSH and free T4 level, and ACTH-cortisol and testosterone levels in males) data and a body CT scan during the treatment period and before and after each infusion of ipilimumab and then at least every 3 months.

When hypophysitis was clinically suspected, these patients were referred to the endocrinologist. All patients had an initial hormonal evaluation: TSH, tri-iodothyronine, T4, 0800 h. ACTH-cortisol, luteinizing hormone, follicle-stimulating hormone, testosterone/estradiol, prolactin, insulin-like growth factor 1 (IGF1), urinary volume, and plasma osmolality, and pituitary imaging (MRI or CT if contraindicated). Ophthalmologic evaluations, using Goldman’s campimetry, were carried out in the ophthalmology department of our hospital at 3 months, and earlier if visual disturbance was suspected. Pituitary dysfunction led to substitutive hormonal treatment. High-dose glucocorticoids (at least 0.5 mg/kg methylprednisolone, prednisolone, or prednisone) were given when necessary and maintained for at least 15 days at maximal dose before a progressive decrease. The decrease in glucocorticoid dose occurred over one to several months, depending on clinical response, especially if other IRAEs were present. Substitutive therapy with hydrocortisone was introduced subsequently after discontinuation of other glucocorticoids. Patients had clinical (assessed by the endocrinologist), hormonal, and imaging follow-up investigations at 3 months, and then at least once yearly.

A deficiency of TSH was defined as a low plasma T4 level (<12 pmol/l) with a low or inappropriately normal TSH level. ACTH deficiency was diagnosed if there was a low cortisol level (<200 nmol/l) with low or inappropriately normal ACTH level at 0800 h. An insulin-tolerance test was then performed if cortisol was found to be between 200 and 360 nmol/l or if there were clinical symptoms (see below) suggesting partial adrenal insufficiency. Gonadotroph deficiency was defined by low plasma sex steroids with inappropriate gonadotrophin levels (normal or low) and amenorrhea in non-menopausal women, or a lack of increase on gonadotrophins in menopausal women. Hyperprolactinemia was defined as a basal plasma prolactin level of >25 ng/ml, and prolactin was considered low when it was <5 ng/ml. Plasma IGF1 was determined in a RIA (Beckman Coulter-Immunotech, Marseille, France) and was standardized according to normal values for age, gender, and, if needed, pubertal status. Posterior pituitary function was assessed by clinical symptoms, as well as by measurement of urinary volume, plasma, and urinary osmolality.

At the 3-month evaluation, when possible, an insulin-tolerance test (insulin 0.1 UI/kg i.v.) was performed, and cortisol and growth hormone (GH) peaks were evaluated. The responses were considered adequate if the cortisol peak was >550 nmol/l and the GH peak was >3 µg/l (with a blood-glucose nadir of <2.2 mmol/l).

A pituitary MRI or CT was performed using sagittal, coronal, and axial sections. MRI sequences were spin-echo T1- and T2-weighted images, followed by post-gadolinium T1-weighted images. Pituitary imaging was performed at diagnosis, at 3 months evaluation, and then yearly when possible.
Statistical analyses
Descriptive statistics with quantitative variables were expressed as their means ± s.d. and, for follow-up, in median with ranges (minimum–maximum). Occurrences of IRAEs, and clinical, hormonal and imaging abnormalities, were expressed as absolute numbers and percentages.

Results
Because some patients are in ongoing randomized trials that are not yet unblinded, the actual incidence of hypophysitis could not be precisely assessed. Depending on the randomization rate, a maximum of 131 patients actually received ipilimumab; of these, 15 experienced hypophysitis, which resulted in a minimum estimated percentage of 11.5%. Among these, two (minimum estimated percentage 2/62, 3.2%) were treated with ipilimumab at a dose of 3 mg/kg, 11 (minimum estimated percentage 11/ 44, 25%) received 10 mg/kg, and two (minimum estimated percentage 2/12, 16.7%) received 3 or 10 mg/kg. All patients had a normal hormonal evaluation before beginning anti-CTLA4 Ab therapy.

Patients’ characteristics
Mean age at diagnosis of hypophysitis was 55.5 ± 11.2 years; most were male patients (ten males and five females) (Table 1). Hypophysitis was diagnosed from February 1, 2010 until August 6, 2012. Patients received their first infusion of ipilimumab between September 30, 2009 and May 31, 2012. They presented the first symptoms of hypophysitis after an average of 9.5 ± 5.9 weeks; two patients (13.3%) after the second infusion of ipilimumab, ten patients (66.7%) after the third infusion, and three patients (20%) after the fourth infusion.

Initial evaluation
At diagnosis, patients usually had non-specific complaints: moderate to severe headache (n = 13), asthenia and weakness (n = 11), decreased libido (n = 3), and dizziness (n = 2). None had visual disturbance, polyuria, or polydipsia.

Endocrine evaluation showed corticotroph deficiency in 11 patients (73.3%), thyrotroph deficiency in 13 (86.6%), and gonadotroph deficiency in 12 patients (85.7%, one patient receiving contraceptive pills could not be evaluated) (Table 1). Two of eight patients had low IGF1 (patients 7 and 13), no insulin-tolerance test was performed on GH in these patients at diagnosis. One had moderate hyperprolactinemia (32 ng/ml, patient 8), whereas 3/9 had a low prolactin level (<5 ng/ml, patient 7, 10, and 13). No patient had diabetes insipidus (Tables 1 and 2).

Overall, one patient had normal pituitary function at diagnosis, one had an isolated pituitary deficiency (hypogonadotroph hypogonadism), whereas the remaining 13 patients had at least two pituitary deficiencies. Eleven patients (seven with a corticotroph deficiency and four with normal corticotroph function) were then treated with high-dose glucocorticoids, while the remaining four patients (who all had a corticotroph deficiency) received substitutive glucocorticoid therapy. Five patients received L-T4 therapy. None received sex-steroid hormone treatment immediately after diagnosis.

All but one of the 15 patients underwent initial imaging of the pituitary (12 MRIs and two CTs) at, on average, 20 ± 17.5 days after diagnosis. Among these, 12 images were considered abnormal by the neuroradiologist (Fig. 1), with a moderately enlarged and homogeneously enhanced pituitary, a convex aspect of the gland, and

Table 1 Characteristics and evolution of patients who presented with autoimmune hypophysitis associated with ipilimumab.

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>At diagnosis</th>
<th>End of follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (years)</td>
<td>55.5 ± 11.2</td>
<td></td>
</tr>
<tr>
<td>Gender ratio (men/women)</td>
<td>2/1</td>
<td></td>
</tr>
<tr>
<td>Duration of follow-up, median (months)</td>
<td>33.6 (7–53.5)</td>
<td></td>
</tr>
<tr>
<td>First symptoms after ipilimumab treatment (weeks)</td>
<td>9.5 ± 5.9</td>
<td></td>
</tr>
<tr>
<td>Hormonal defects (n = patients/number of data)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticotroph</td>
<td>11/15</td>
<td>13/15</td>
</tr>
<tr>
<td>Thyrotroph</td>
<td>13/15</td>
<td>2/15</td>
</tr>
<tr>
<td>Gonadotroph</td>
<td>12/14</td>
<td>2/15</td>
</tr>
<tr>
<td>Somatotroph</td>
<td>2/8</td>
<td>1/11</td>
</tr>
<tr>
<td>Lactotroph</td>
<td>3/9</td>
<td>1/11</td>
</tr>
<tr>
<td>Diabetes insipidus</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hyperprolactinemia</td>
<td>1/9</td>
<td></td>
</tr>
<tr>
<td>Hormone replacement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>11/15</td>
<td>13</td>
</tr>
<tr>
<td>Thyroxin</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Sex hormones</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Imaging abnormalities (n = patients/number of data)</td>
<td>12/14</td>
<td>11/14</td>
</tr>
</tbody>
</table>

*aLow IGF1.
*bAn insufficient GH peak in an insulin-tolerance test and low IGF1 (eight insulin-tolerance tests were performed).
*cSeven high-doses and four replacement doses, and four patients with no defects received high-dose glucocorticoids for hypophysitis.
Table 2 Patients who presented with ipilimumab-induced hypophysitis: at diagnosis.

<table>
<thead>
<tr>
<th>Patient (ipilimumab dose)</th>
<th>Age at diagnosis/ gender</th>
<th>Time/number of infusions to diagnosis (weeks)</th>
<th>Follow-up (months)</th>
<th>Symptoms at diagnosis</th>
<th>Corticotroph deficiency (D)</th>
<th>Treatment</th>
<th>Thyrotroph or gonadotroph deficiency (treatment)</th>
<th>Imaging (time to diagnosis, days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (3 mg/kg)</td>
<td>45.8/M</td>
<td>9.0/3</td>
<td>11.4</td>
<td>H+A</td>
<td>Y</td>
<td>GC HD</td>
<td>Td+G</td>
<td>EP (7)</td>
</tr>
<tr>
<td>2 (3 mg/kg)</td>
<td>60.9/M</td>
<td>6.7/3</td>
<td>22.1</td>
<td>H+A</td>
<td>N</td>
<td>GH HD</td>
<td>G</td>
<td>EC (4)</td>
</tr>
<tr>
<td>3 (10 mg/kg)</td>
<td>80.3/M</td>
<td>9.4/3</td>
<td>37.5</td>
<td>H+A</td>
<td>Y</td>
<td>GC HD</td>
<td>Td(T)+G</td>
<td>NA</td>
</tr>
<tr>
<td>4 (10 mg/kg)</td>
<td>43.8/M</td>
<td>3.1/2</td>
<td>33.6</td>
<td>H+A</td>
<td>N</td>
<td>GC HD</td>
<td>N</td>
<td>EC (58)</td>
</tr>
<tr>
<td>5 (10 mg/kg)</td>
<td>47.8/F</td>
<td>9.0/3</td>
<td>32.4</td>
<td>H</td>
<td>Y</td>
<td>GC HD</td>
<td>Td(T)</td>
<td>EP (14)</td>
</tr>
<tr>
<td>6 (10 mg/kg)</td>
<td>54.1/M</td>
<td>5.7/3</td>
<td>15.9</td>
<td>H+A+DL</td>
<td>Y</td>
<td>GC HD</td>
<td>Td+G</td>
<td>EC (24)</td>
</tr>
<tr>
<td>7 (10 mg/kg)</td>
<td>61.8/M</td>
<td>28.1/4</td>
<td>52.5</td>
<td>H+A+Di</td>
<td>Y</td>
<td>GC HD</td>
<td>Td(T)+G</td>
<td>EC (54)</td>
</tr>
<tr>
<td>8 (10 mg/kg)</td>
<td>46.5/F</td>
<td>13.9/4</td>
<td>47.4</td>
<td>H</td>
<td>Y</td>
<td>GC</td>
<td>Td+G</td>
<td>EC (28)</td>
</tr>
<tr>
<td>9 (10 mg/kg)</td>
<td>52.1/M</td>
<td>7.1/3</td>
<td>49.6</td>
<td>H+A+DL</td>
<td>N</td>
<td>GC HD</td>
<td>Td(T)+G</td>
<td>EP+EC (31)</td>
</tr>
<tr>
<td>10 (10 mg/kg)</td>
<td>39.8/M</td>
<td>9.3/3</td>
<td>43.1</td>
<td>H</td>
<td>Y</td>
<td>GC HD</td>
<td>Td+G</td>
<td>EP+EC+EPS (18)</td>
</tr>
<tr>
<td>11 (10 mg/kg)</td>
<td>67.7/M</td>
<td>9.3/3</td>
<td>27.5</td>
<td>H+A+DL+Di</td>
<td>N</td>
<td>GC HD</td>
<td>Td+G</td>
<td>EP+EC (6)</td>
</tr>
<tr>
<td>12 (10 mg/kg)</td>
<td>50.5/F</td>
<td>9.9/4</td>
<td>39.8</td>
<td>A</td>
<td>Y</td>
<td>GC</td>
<td>Td+NA</td>
<td>CT: EP+EC+EPS (9)</td>
</tr>
<tr>
<td>13 (3 vs 10 mg/kg)</td>
<td>59.0/F</td>
<td>7.0/3</td>
<td>25.7</td>
<td>H</td>
<td>Y</td>
<td>GC</td>
<td>Td(T)+G</td>
<td>EP+EC (13)</td>
</tr>
<tr>
<td>14 (10 mg/kg)</td>
<td>67.0/M</td>
<td>6.0/2</td>
<td>43.0</td>
<td>A</td>
<td>Y</td>
<td>GC HD</td>
<td>Td+G</td>
<td>EC (6)</td>
</tr>
<tr>
<td>15 (3 vs 10 mg/kg)</td>
<td>60.7/F</td>
<td>9.6/3</td>
<td>7.0</td>
<td>H+A</td>
<td>Y</td>
<td>GC</td>
<td>Td+G</td>
<td>TDM: EC+EPS (8)</td>
</tr>
</tbody>
</table>

M, male; F, female. Symptoms: H, headache; A, asthenia; DL, decreased libido; Di, dizziness; Y, yes; N, no; GC, glucocorticoids; HD, high dose; Td, thyrotroph deficiency; T, T-thyroxin; G, gonadotroph deficiency; NA, not available. Imaging: EP, enhanced pituitary; EC, enhanced contrast; EPS, enhanced pituitary stalk; CT, computed tomography.

Follow-up period

The median length of follow-up was 33.6 months, range 7–53.5 months after hypophysitis, or 34.5 months, range 9.3–60 months after the initiation of ipilimumab. Five patients died from progressive metastatic melanoma. Eleven patients presented with IRAEs; the most frequent were enterocolitis and diarrhea (n=6), and rash or other adverse autoimmune skin-related events (n=5). No other immune-related endocrine disease was observed in these patients, and eight were negative for thyroid antibodies. By the end of the follow-up period, seven patients had stopped ipilimumab due to progression of disease, five because of adverse events (discontinuation because of pituitary side-effects for two patients), and the three others were still ongoing ‘post-ipilimumab follow-up without treatment’.

All patients had rapid improvement of clinical symptoms in the first month after beginning glucocorticoid therapy. Two patients developed corticotroph deficiency at the end of glucocorticoid treatment. None of the 13 patients showed recovery of corticotroph function at the end of the follow-up period. Eleven patients recovered normal thryotroph and ten patients recovered normal gonadotroph functions. One patient had IGF1 (patient 7) and two patients’ prolactin levels (patient 7 and 10) normalized during the follow-up.

Overall, at the last follow-up, 13 patients had corticotroph deficiency (all treated with physiological replacement doses of hydrocortisone), two had thyrotroph deficiency (both received substitutive treatments), two had gonadotroph deficiency (one man received testosterone, introduced during follow-up), and one patient had a somatotroph deficiency (patient 13; on eight insulin-tolerance test). One patient still had hyper-prolactinemia (patient 8) and one of 11 patients had a low prolactin level (patient 13). There was still no occurrence of diabetes insipidus (Tables 1 and 3).

Fourteen patients had early re-evaluation of pituitary images during the follow-up period: 12 MRIs and two CTs, at a mean time of 7.2±4.3 months. Eleven of these showed abnormalities (Fig. 1), including decreased pituitary volume, a concave pituitary aspect or an empty sella turcica. The images became normalized in three patients during the follow-up (all three had received high-dose glucocorticoids as the initial treatment).

Discussion

This study is the first large series to conduct analyses, during a more than 2.5-year median follow-up period, on the clinical, hormonal, and imaging statuses of patients treated with ipilimumab (CTLA4 Ab) for malignant melanoma and who presented with autoimmune hypophysitis. Indeed, most publications on ipilimumab-induced hypophysitis are usually case reports.
Our aim was to deduce, from these detailed data, the most appropriate monitoring method and follow-up for such patients, to provide relevant and informed advice.

In our study, the prevalence of hypophysitis in patients receiving ipilimumab was significant, although this could not be assessed precisely due to the ongoing blinding of several cases in our series. The lowest estimation of its incidence, based on the hypothesis that all still unblinded cases had received ipilimumab, was 11.5% (15 cases in 131 patients), with a 3% incidence (two cases in 62 patients) with 3 mg/kg, and a 25% incidence (11 cases in 44 patients) in the group of patients that received ipilimumab at 10 mg/kg, which is greater than previously reported. Indeed, the reported frequency of hypophysitis in the literature ranges from 0 to 17%, depending on dose and study (18, 21, 23, 25, 26). Thus, this IRAE seems to be dose dependent. The relationship between dose of ipilimumab and IRAEs is common, and seems also to be correlated with the antitumor response (13, 16, 17, 18). This dose-dependency has already been pointed out by Maker et al. (25) who found that a majority of patients who experience hypophysitis received a higher dose of ipilimumab (i.e. 9 mg/kg).

The higher prevalence of hypophysitis in our study could, in part, be related to the ongoing increased experience of clinicians, who are nowadays more vigilant regarding the symptoms of this potentially life-threatening IRAE; thus, systematic hormonal monitoring is practiced in our center.

In our study, patients’ clinical presentations are atypical for hypophysitis. Autoimmune lymphocytic hypophysitis is reported to be more commonly observed in females (six women compared with one man), with a strong association with pregnancy, and a predominant occurrence in patients aged in their 30s for females and in their early 40s for males (5, 27). In contrast, in this study, the gender ratio favored men (two men: one woman); a male preponderance has been also noted in other studies (19, 28). Our patients were also older, with a mean age of 55.2 years at diagnosis. Moreover, even if the initial symptoms, although not specific, were reminiscent of that observed in other forms of hypophysitis (headache, asthenia), the symptoms observed related to mass effect were moderate: there was no visual disturbance and so no surgical decompression was necessary in our patients. Our patients presented with pituitary deficiencies, which usually affected several hormones (13/15), especially thyrotroph (86.6%), gonadotroph (85.7%), and corticotroph deficiencies (73.3%), with only one case of hyperprolactinemia (11.1%) and no cases of diabetes insipidus.

In lymphocytic hypophysitis, the most commonly described defect affects the corticotroph axis (32%), and 18 and 31% of patients present with hyperprolactinemia and diabetes insipidus respectively (6). Note that, in our study, at diagnosis of hypophysitis, one patient did not...
have any pituitary defect and two had normal imaging. Such particular features make ipilimumab-induced hypophysitis a special entity, which has different characteristics at diagnosis and that specialists should be aware of. Nevertheless, regarding its evolution, it seems that it is not too different from the natural history of previously described autoimmune hypophysitis, with rapid improvement in clinical symptoms and that required ongoing hormone replacement in all but two patients by the end of the follow-up (13.3%), and shrinkage of the tumor mass at imaging re-evaluation with normalization (3/14) or a decrease in pituitary volume (11/14) (5). This atypical hormonal presentation could, in part, be explained by the recent findings of Iwama et al. (29) who found that, in seven patients with hypophysitis and treated with ipilimumab, antibodies recognizing predominantly TSH-secreting cells (7/7) and also follicle-stimulating hormone- (5/7) and ACTH- (3/7) secreting cells appeared. In the same study, the expression of CTLA4 in TSH- and PRL-secreting cells has been detected in the pituitary gland.

Our study has improved the description of the kinetics of hypophysitis after starting ipilimumab therapy. Indeed, most of our patients (10/15) presented with their first symptoms after the third infusion, at a mean time of 9.5 weeks after starting treatment; this corroborates with a recent analysis of 325 patients who were treated with 10 mg/kg of ipilimumab, where it took an average of 9 weeks before the onset of endocrine adverse events (mainly hypophysitis, in 3% of patients, considered grade 3 or 4 IRAEs) (13). Also, the study by Min et al. (24) has reported a 9.4 week period before the onset of hypophysitis in eight patients who received 10 mg/kg of ipilimumab. These observations indicate that closer follow-up is needed during this period, which includes intensification of clinical and biological monitoring, and also imaging when hypophysitis is suspected. Our study also confirms the moderate degree of pituitary enlargement that occurred in hypophysitis associated with ipilimumab. However, despite the lack of visual disturbance in our series, two patients have been reported in the literature (20). Our study confirms that, in this setting, the involvement of the posterior pituitary is extremely rare, with only one case of diabetes insipidus described in the literature (11).

One of the crucial points with IRAEs that develop in association with ipilimumab, especially hypophysitis, is the attitude regarding treatment: should high-dose glucocorticoids be systematically administrated and should ipilimumab be stopped after the occurrence of hypophysitis? Different studies have not shown any deleterious effects of high-dose glucocorticoid therapy in cases of IRAEs associated with ipilimumab antitumor responses, and the duration of tumor response does not seem to be affected by this treatment (18, 23, 30). Moreover, in our study, as in another analysis (23), high-dose glucocorticoids did not seem to change the natural history of hypophysitis, especially concerning life-threatening corticotroph function: patients who had a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23). All four patients who did not have a corticotroph defect at diagnosis still had this defect at the end of the follow-up period, irrespective of the type of glucocorticoid treatment, be it high-dose or a physiological replacement dose (23).
deduce strict recommendations. However, in a recent study, Lammert et al. (31) have observed complications in five out of seven patients (four who needed to be hospitalized) after administration of high-dose corticosteroids for ipilimumab-induced hypophysitis, and partial or complete hypopituitarism remained in all patients. Thus, we suggest that high-dose glucocorticoids are proposed for patients with ipilimumab-induced hypophysitis who have serious mass-effect-related symptoms, such as severe headache, visual-field disturbance, or simultaneously presence of other IRAEs. Physiological replacement doses should be considered for others with corticotroph deficiency because pharmacologic glucocorticoid therapy was not clearly associated with improved outcomes in such patients. Concerning interrupting CTLA4 Ab treatment, most authors agree that the benefits of ipilimumab, regarding survival in the context of a potentially fatal malignancy, greatly outweigh the risks of continuing therapy using an appropriate substitutive treatment (13, 20, 32, 33). We believe that such patients should not have ipilimumab treatment interrupted after adapted management of hypophysitis; most of our patients continued their ipilimumab treatment without recurrence of any clinical symptoms. However, the discussion about the risks–benefits would be different in an anti-CTLA4 adjuvant setting, and the decision regarding treatment should be made after the patient has been fully informed of the risk of hypophysitis and corticotroph defect that usually persists: in our study there were no recoveries and, in the literature, only two recoveries have been reported (18, 19). Noteworthy in a recent study, the development of hypophysitis has been associated with a better outcome in patients with metastatic melanoma (19). Unfortunately, it is impossible to do so in our study, because several patients are included in clinical trials that are still blinded. Furthermore, a majority of the patients who presented hypophysitis in our study received 10 mg/kg ipilimumab as an adjuvant treatment for melanoma with positive lymph nodes and no other evidence of metastatic disease spread (stage-III malignant melanoma). In these patients with less severe disease than metastatic melanoma, two died during follow-up, so a longer follow-up would be necessary to assess survival benefit.

This study was conducted in a single center, which may represent both a strength in terms of homogeneity of data, but also a limitation in terms of recruitment and management choice. Before a referent endocrinologist became systematically involved in September 2010, the management of such cases had been relatively heterogeneous and initial evaluation was sometimes incomplete, which explains the missing values in our analyses. Moreover, until September 2010, patients had received high-dose glucocorticoids regardless of the clinical symptoms, and the cause of the corticotroph defects in these patients could be questioned: did they occur secondary to hypophysitis or to the high-dose glucocorticoid treatment? Evolution should permit us to answer this question. It is noteworthy that, in our study, diagnosis of hypophysitis was presumptive (clinical symptoms associated with hormonal or imaging abnormalities (6)), but no patient had any surgical indications (persistent headache, severe visual disturbance...), as pituitary enlargement is usually only moderate in this type of hypophysitis. Indeed, no previous study has reported anatomo-pathological analysis until now (19). Moreover, we did not perform a systematic pituitary MRI in all ipilimumab-treated patients: thus, it is possible that we underestimated the prevalence of ipilimumab-induced hypophysitis. Indeed, some authors have reported that progressive pituitary enlargement can be an early and sensitive tool in such diagnosis (19). Although routine MRIs cannot be recommended, nor can 18-FDG PET-CTs, which seems to be also an interesting tool for the early detection of hypophysitis associated with ipilimumab (34), these methods could be considered after the third injection of ipilimumab.

Overall, it should be kept in mind that diagnosis of hypophysitis after CTLA4 Ab therapy is, most of the time, presumptive and explorations during the follow-up period need to be systematic and frequent. It should include clinical, biological, and sometimes imaging, with particular attention given after the third infusion of ipilimumab. This need for close monitoring is all the more justified as the prevalence of hypophysitis associated with ipilimumab seems to be higher than was initially presumed, especially when given at a dose of 10 mg/kg: at least one in four patients presented with hypophysitis at this dose. Thyrotroph, gonadotroph, and corticotroph functions seem to be the most affected, with thyrotroph and gonadotroph functions usually recovering during follow-up. However, particular attention needs to be paid to corticotroph function, which has a possible delayed onset and may not recover, as in our study, for almost 3 years: thus, prolonged treatment is required and the patient needs to receive appropriate education regarding this long-term medication, with a long-term multi-disciplinary follow-up.

In the future, with the increased number of clinical trials on CTLA4 Ab and the development of new
immunomodulatory drugs, the physicians in charge of these patients should be aware and updated guidelines should be elaborated and disseminated. Interestingly, it seems that hypophysitis is much more frequently associated with ipilimumab treatment than with other immunomodulatory drugs (hypophysitis <1% with nivolumab, immunomodulatory drug evaluated in various type of cancer, Ab against programed death 1, inhibitor receptor expressed by activated T cells) (35, 36). Furthermore, new research on pituitary immunity and the ongoing development of sensible and specific antibodies should help us to increase diagnostic accuracy and to monitor this pathology (29, 37).

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the ‘Association pour le Développement de la Recherche Médicale au Centre Hospitalier Universitaire de Marseille’ (ADEREM).

References


